## NDAQ: Nasdaq, Inc. - XLF: Financial Services

### Executive Summary

VALUE thesis: PEG 1.49 indicates fundamental undervaluation. Analyst consensus $112 (+12% upside). Consistent execution (4/4 quarters beat estimates). Caution: overbought RSI (73).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($97.45)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. Maryland Representative April McClain Delaney Purchased as Much as $135,000 in Bio-Techne Shares**
- Source: Bitget | 20260105T230912 | Somewhat-Bullish | Relevance: 83%
- Maryland Representative April McClain Delaney recently purchased between $9,009 and $135,000 worth of Bio-Techne (NASDAQ: TECH) shares on December 2, 2025. This transaction is part of her 147 stock trades over the past three years, totaling over $371,000, and highlights the ongoing requirement for transparency in congressional stock transactions under the STOCK Act. Monitoring such trades can offer insights for investors, though they should not be the sole basis for investment decisions.

**2. Intercontinental Exchange: The Quiet Infrastructure Powering Global Markets’ Next Upgrade**
- Source: AD HOC NEWS | 20260105T013128 | Neutral | Relevance: 74%
- Intercontinental Exchange (ICE) has transformed from an exchange operator into a comprehensive market infrastructure and data platform. Its integrated ecosystem offers global exchanges and clearing, data analytics through ICE Data Services, mortgage technology, and benchmark administration, providing a unified solution for trading, risk management, and data needs. This strategic diversification and vertical integration position ICE as a resilient and essential player in the modernization of global finance, influencing its strong stock performance.

**3. Maryland Representative April McClain Delaney Purchased as Much as $135,000 in Bio-Techne Shares**
- Source: Bitget | 20260106T150825 | Neutral | Relevance: 72%
- Maryland Representative April McClain Delaney recently purchased between $9,009 and $135,000 worth of Bio-Techne (NASDAQ: TECH) shares on December 2, 2025. This transaction is part of her extensive trading activity over the past three years, totaling over $371,000 across 147 stock trades. Congressional members are required to disclose such transactions under the STOCK Act, which aims to prevent the use of insider information for personal financial gain.

**4. Bonk, Inc. Regains Compliance with Nasdaq Minimum Bid Price Requirement**
- Source: Lohud | 20260106T140853 | Somewhat-Bullish | Relevance: 64%
- Bonk, Inc. announced it has regained compliance with Nasdaq's minimum bid price requirement, ensuring its continued listing on The Nasdaq Capital Market. The company's common stock maintained a closing bid price of $1.00 or more for 10 consecutive business days from December 11 to December 24, 2025. This achievement was critical for the company, affirming strategic capital restructuring decisions and allowing a renewed focus on growth and execution.

**5. Ação da Goldman Sachs atinge máxima histórica de US$ 920,01**
- Source: Investing.com Brasil - Finanças, Câmbio e Investimentos | 20260105T151006 | Neutral | Relevance: 60%
- A ação da Goldman Sachs Group Inc. atingiu um novo recorde histórico de US$ 920,01, impulsionada por um aumento de 61,29% no último ano e desempenho superior aos concorrentes, com margens de lucro saudáveis e alto retorno sobre o patrimônio. A empresa está envolvida em iniciativas estratégicas, incluindo o financiamento de Kennedy Wilson e um investimento na Bolsa de Valores do Texas, além de liderar uma rodada de financiamento para a Skims, de Kim Kardashian. Analistas como o BofA Securities elevaram seu preço-alvo para a Goldman Sachs para US$900, mantendo a classificação de Compra.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-22 | Morgan Stanley | $111 | $110 | +1% |
| 2025-12-12 | Barclays | $114 | $109 | +5% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-22 | Morgan Stanley | main | Overweight |
| 2025-12-12 | Barclays | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 5 ($2.65M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 49.0% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Vanguard Group Inc: 10.4% (+6.9%)
- Investor AB: 10.2% (0.0%)
- Blackrock Inc.: 7.0% (+8.3%)
- Wellington Managemen: 7.0% (-3.5%)
- Massachusetts Financ: 4.6% (-3.3%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.49 suggests fair value with growth premium. Forward P/E 26.3x stretched relative to 12% growth. Quality metrics strong (margin 20%). Insider selling cluster ($2.7M in 90 days), potential headwind. Institutional flow bearish (5 selling vs 4 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $57.8B |
| Beta | 1.02 |
| 52W Range | $64.84 - $100.80 |
| Short Interest | 1.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.49 |
| Forward P/E | 26.3 |
| Current P/E | 29.4 |
| YoY Growth | 11.6% |
| EPS Direction | STABLE |

### Technicals

MRS_20 stable at 4.4% (minimal 5-day change). Currently in lower STRENGTH zone (4.0-10.0%), cross-sectional ranking at 78th percentile. MRS_5 at 1.7% confirms short-term momentum alignment. AM_20 at 5.3% shows strong absolute momentum above own 20MA. Full SMA alignment bullish (above 20/50/200 SMAs). RSI overbought at 73, risk of mean reversion. OFD pattern: +FTN (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 4.44% (CS: 78) | Strong |
| RSI_14 | 73.3 | Overbought |
| MACD Histogram | 0.15 | Bullish |
| vs SMA20 | 1.053x | Above |
| vs SMA50 | 1.108x | Above |
| vs SMA200 | 1.153x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $100.69
- **Stop Loss:** $97.45 (3.2% risk)
- **Target:** $107.17 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 407
- **Position Value:** $40,980.83
- **Portfolio %:** 40.98%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | RISK_ON (MEDIUM) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*RISK_ON regime with strong participation and low volatility. VIX at 14.75 (6th percentile) with breadth at 63.5% signals healthy risk appetite. Fed dovish expectations and AI/semiconductor momentum are primary drivers, though elevated put/call ratio suggests smart money hedging. Focus on quality growth with awareness of potential complacency.*

### Earnings

**Next:** 2026-01-28 (Est: $0.91)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.85 | $0.88 | +3.7% |
| 2025Q2 | $0.81 | $0.85 | +4.6% |
| 2025Q1 | $0.77 | $0.79 | +2.5% |
| 2024Q4 | $0.75 | $0.76 | +1.4% |

---
*RULE-based L3 | 2026-01-07 08:25 | MRS_20*